BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18219094)

  • 1. Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters.
    Tsai WC; Chu CH; Yu CP; Sheu LF; Chen A; Chiang H; Jin JS
    Dis Markers; 2008; 24(2):89-99. PubMed ID: 18219094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the serine protease, matriptase, in breast ductal carcinoma of Chinese women: correlation with clinicopathological parameters.
    Jin JS; Cheng TF; Tsai WC; Sheu LF; Chiang H; Yu CP
    Histol Histopathol; 2007 Mar; 22(3):305-9. PubMed ID: 17163404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women.
    Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F
    J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
    Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
    Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of survivin in different stages of carcinogenesis and progression of breast cancer].
    Zhang SQ; Qiang SY; Yang WB; Jiang JT; Ji ZZ
    Ai Zheng; 2004 Jun; 23(6):697-700. PubMed ID: 15191674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma.
    Adamkov M; Kajo K; Vybohova D; Krajcovic J; Stuller F; Rajcani J
    Neoplasma; 2012; 59(1):30-7. PubMed ID: 22103896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
    Rehman S; Crow J; Revell PA
    Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome.
    Yoon NK; Seligson DB; Chia D; Elshimali Y; Sulur G; Li A; Horvath S; Maresh E; Mah V; Bose S; Bonavida B; Goodglick L
    Cancer Biomark; 2009; 5(4):215-24. PubMed ID: 19729831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome.
    Nassar A; Lawson D; Cotsonis G; Cohen C
    Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):113-20. PubMed ID: 18227733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal expression of Nek2 and β-catenin in breast carcinoma: clinicopathological correlations.
    Wang S; Li W; Lv S; Wang Y; Liu Z; Zhang J; Liu T; Niu Y
    Histopathology; 2011 Oct; 59(4):631-42. PubMed ID: 22014044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: tissue microarray analysis of immunohistochemical scores with clinicopathological parameters.
    Tsai WC; Chao YC; Lee WH; Chen A; Sheu LF; Jin JS
    Histopathology; 2006 Oct; 49(4):388-95. PubMed ID: 16978202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.
    Kominsky SL; Argani P; Korz D; Evron E; Raman V; Garrett E; Rein A; Sauter G; Kallioniemi OP; Sukumar S
    Oncogene; 2003 Apr; 22(13):2021-33. PubMed ID: 12673207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoplasmic FOXP1 expression is correlated with ER and calpain II expression and predicts a poor outcome in breast cancer.
    Yu BH; Li BZ; Zhou XY; Shi DR; Yang WT
    Diagn Pathol; 2018 May; 13(1):36. PubMed ID: 29848352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Detection and clinical significance of Notch1 methylation in breast cancer and intraductal proliferative breast lesions].
    Zhang N; Sun ZZ; Li F; Cao YW; Zhao CX; Liang WH; Sun HP; Li HA; Fu XG
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):324-9. PubMed ID: 21756827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.